ALBANY, N.Y., May 22, 2012 /PRNewswire/ -- AMRI (NASDAQ: AMRI), a leading global contract research and manufacturing organization, announced today the appointment of Ian Shott as President of AMRI Europe, reporting to Thomas D'Ambra, Ph.D., chairman, president and CEO. In this newly created role, Mr. Shott will have responsibility for AMRI's business operations in Europe, including the company's site in Wales, United Kingdom, and work closely with AMRI's European-based business development team. As the founder of Excelsyn, acquired by AMRI in 2010, and with more than 20 years experience working with global pharmaceutical, biotechnology, and chemical companies, Mr. Shott will be instrumental in leading AMRI's sales growth in European markets as well as the worldwide effort to continue to expand revenue growth at the Wales manufacturing location.
Mr. Shott was the founder and CEO of Excelsyn – now AMRI UK – acquired in
February 2010 to expand the company's services platform and footprint in
Europe. Mr. Shott serves as Managing Director of Shott Consulting Limited, where he provides consulting services to the health care and chemical industries, as well as leading Industry Boards for the British Government in Science, Technology, Innovation and Business Development.
"Mr. Shott brings an intimate knowledge of the AMRI UK site including its capabilities and leadership team, which will enable him to quickly embark on customer and business growth initiatives," Dr. D'Ambra said. "His extensive experience and skills strengthen our position in the European marketplace. Over the years Mr. Shott has built a reputation as a leader and senior level statesman in the CRO/CMO business space with key relationships in the European and North American healthcare community. His unique insights are a good fit with our AMRI SMARTSOURCING ™ brand and I look forward to his contributions in building strategic relationships with a broader customer base, which benefits all of our locations."
Mr. Shott's earlier career included executive board posts at RhodiaChirex in France, Chirex in the United States, Lonza in Switzerland, and Astra Zeneca in the United Kingdom. He has been particularly involved in creating and/or transforming businesses by a combination of break out development, culture change, organic growth, internal re-engineering and external merger, acquisition and divestment.Mr. Shott said, "I believe AMRI has assembled a highly distinctive combination of skills, capabilities and capacities across three continents and can provide unparalleled solutions to customer needs. I am extremely excited at helping to develop business in Europe in a rapidly changing business environment." About AMRI Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development, and manufacturing services. For over 21 years AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING ™, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development. AMRI UK provides development and manufacturing services, including pre-clinical and Phase I – III product development, as well as commercial manufacturing for approved products. The 14-acre site is located about 60 miles outside of Manchester, England and contains Kilo lab, pilot plant and large-scale manufacturing capabilities. In 2012, the site received a Good Manufacturing Practice (GMP) certificate from the Medicines and Healthcare Regulatory Agency (MHRA) of the UK government for AMRI's manufacturing facility in Holywell, Wales, UK, underscoring the quality of the facility and its growth potential.